Трансдермальная контрацепция (обзор литературы)

1. Прилепская В.Н. Новые возможности и перспективы современной контрацепции (клиническая лекция). Проблемы репродукции. 2009; 5: 63–5.
2. Прилепская В.Н., Назарова Н.М. Новые технологии в контрацепции: гормональные рилизинг-системы. Гинекология. 2005; 1 (7).
3. Прилепская В.Н., Назарова Н.М. Трансдермальная контрацептивная система ЕВРА. Фарматека. 2005; 15: 8–10.
4. Сабуров А.В. Современная гормональная контрацепция. Новая аптека. 2009; 11: 144–8.
5. Audet MC, Moreau M, Koltun WD et al. for the ORTHO EVRA/EVRA 004 Study Group: Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285 (18): 2347–54.
6. Archer DF, Bigrigg A, Smallwood GH et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 2002; 77 (Suppl. 2): S27–31.
7. Archer DF, Cullins V, Creasy GW, Fisher AC. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 2004; 69 (3): 189–95.
8. Abrams LS, Skee DM, Natarajan J, Wong FA. Pharmacokinetic overview of Ortho Evra™/Evra™. Fertil Steril 2002; 77 (Suppl. 2): S3–12.
9. Abrams LS, Skee DM, Natarajan J et al. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br J Clin Pharmacol 2002; 53 (2): 141–6.
10. Abrams LS, Skee DM, Natarajan J et al. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. J Clin Pharmacol 2001; 41 (12): 1301–9.
11. Audet MC, Moreau M, Koltun WD et al. ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285 (18): 2347–54.
12. Piccoli A, Crosignani PG, Nappi C et al. Effect of the contraceptive patch with ethinylestradiol and norelgestrominom on body composition. Results of bioelectrical impedance analysis performed in a population of women from Italy. Nutr J 2008; 7: 21 doi:10.1186/1475-2891-7-21.
13. Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol 2007; 197 (2): 134.e1–134.e6.
14. Boston Collaborative Drug Surveillance Program. Postmarketing Study of ORTHO EVRA® and Levonorgestrel Oral Contraceptives in Relation to Non-Fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction 2002–2006.
15. Creasy GW, Abrams LS, Fisher AC. Transdermal contraception. Semin Reprod Med 2001; 19 (4): 373–80.
16. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109 (2 Pt 1): 339–46. Erratum in: Obstet Gynecol 2008; 111 (6): 1449.
17. Dittrich R, Parker L, Rosen JB et al. Ortho Evra/Evra 001 Study Group. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. Am J Obstet Gynecol 2002; 186 (1): 15–20.
18. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress. Prescrire Int 2004; 13 (72): 123–6.
19. Frost JJ, Darroch JE, Remez L. Improving contraceptive use in the United States. In Brief. New York: Guttmacher Institute 2008.
20. Goebelsmann U, Mashchak CA, Mishell DR Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 1985; 151 (7): 868–77.
21. Graziottin A. A review of transdermal hormonal contraception. Focus on the ethinylestradiol/norelgestromin contraceptive patch. Treat Endocrinol 2006; 5 (6): 359–65.
22. Gallo MF, Grimes DA, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2003; 1: CD003552.
23. Harel Z, Riggs S, Vaz R et al. Adolescents' experience with the combined estrogen and progestin transdemal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol 2005; 18: 85–90.
24. Jakimiuk A, Madalenet P, Chernev T et al. Transdermal contraception is associated with high levels of patient satisfaction and compliance [abstract]. Eur J Contracept Reprod Health Care 2006; 11 (Suppl. 1): P028 68–9.
25. Jakimiuk A, Madalenet P, Chernev T et al. Efficacy and tolerability of transdermal hormonal contraception over 6 months[abstract]. Eur J Contracept Reprod Health Care 2006; 11 (Suppl. 1): P024 66–7.
26. Johnson JV, Lowell J, Badger G, Cushman M. The effects of oral and transdermal hormonal contraception on coagulation factors: a prospective, randomized, cross-over trial. Presented at: Society for Gynecologic Investigation. Toronto, ON, Canada 2006.
27. Jick S, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006; 73 (3): 223–8.
28. Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2007; 76 (1): 4–7.
29. Kubba A, Guillebaud J, Anderson RA, MacGregor EA. Contraception. The Lancet 2000; 356: 1913–9.
30. Kost K, Singh S, Vaughan B et al. Estimates of contraceptive failure from the 2002 national survey of family growth. Contraception 2008; 77 (1): 10–21.
31. LaGuardia KD, Fisher AC, Bainbridge JD et al. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril 2005; 83 (6): 1875–7.
32. Logsdon S, Richards J, Omar HA. Long-term evaluation of the use of the transdermal contraceptive patch in adolescents. Scient W J 2004; 14: 512–6.
33. Murthy AS, Creinin MD, Harwood B, Schreiber CA. Same-day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditional initiation methods. Contraception 2004; 72 (5): 333–6.
34. Petitti DB: Combination estrogen-progestin oral contraceptives. NEJM 2003; 349: 1443–50.
35. Potter L, Oakley D, de Leon-Wong E, Cañamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996; 28 (4): 154–8.
36. Jakimiuk AJ, Crosignani PG, Chernev T et al. Hhigh levels of womens satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study. Gynecol Endocrinol 2010; Early Online: 1–8.
37. Current status and future potential of transdermal drug delivery. Nature Rev Drug Discov 2004; 3 (2): 115–24.
38. Prilepskaya VN, Kabacibo C, Lee E et al. Book of abstract. 12th World congress on Human Reproduction, Venice, 2005.
39. Pierson RA, Archer DF, Moreau M et al for the ORTHO EVRA/EVRA 008 Study Group: Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003; 80 (1): 34–42.
40. Paris F, Rabeolina F, Balaguer P et al. Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line. Gynecol Endocrinol 2007; 23 (4): 193–7.
41. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998; 30: 89–92.
42. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283–8.
43. Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5-alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14 (4): 223–30.
44. Rubinstein ML, Halpern-Felsher BL, Irwin CE Jr. An evaluation of the use of the transdermal contraceptive patch in adolescents. J Adolesc Health 2004; 34 (5): 395–401.
45. Suwanmalee O, Taneepanichskul S. A clinical study of transdermal contraceptive patch in Thai women. J Med Assoc Thai 2006; 89 (Suppl. 4): S1–4.
46. Smallwood GH, Meador ML, Lenihan JP Jr et al. for the ORTHO EVRA/EVRA 002 Study Group: Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001; 98 (5 Pt 1): 799–805.
47. Schindler AE, Campagnoli C, Druckmann R et al. Classification and pharmacology of progestins. Maturitas 2003; 46 (Suppl. 1): S7–16.
48. Stewart FH, Kaunitz AM, Laguardia KD et al. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol 2005; 105 (6): 1389–96.
49. Sibai BM, Odlind V, Meador ML et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002; 77 (Suppl. 2): S19–S26.
50. Thurman AR, Hammond N, Brown HE, Roddy ME. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch? J Pediatr Adolesc Gynecol 2007; 20 (2): 61–5.
51. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol 2005; 192 (6): 2055–9.
52. World Health Organization. Medical Eligibility Criteria for Contraceptive Use: 2008 update. World Health Organization, Geneva, Swtizerland 2008.
53. Zieman M, Guillebaud J, Weisberg E et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77 (Suppl. 2): S13–8.
54. Zacur HA, Hedon B, Mansour D et al. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 2004; 77 (Suppl. 2): S32–S35.
55. Zacur HA, Hedon B, Mansour D et al. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 2002; 77 (Suppl. 2): S32–S35.

________________________________________________

1. Прилепская В.Н. Новые возможности и перспективы современной контрацепции (клиническая лекция). Проблемы репродукции. 2009; 5: 63–5.
2. Прилепская В.Н., Назарова Н.М. Новые технологии в контрацепции: гормональные рилизинг-системы. Гинекология. 2005; 1 (7).
3. Прилепская В.Н., Назарова Н.М. Трансдермальная контрацептивная система ЕВРА. Фарматека. 2005; 15: 8–10.
4. Сабуров А.В. Современная гормональная контрацепция. Новая аптека. 2009; 11: 144–8.
5. Audet MC, Moreau M, Koltun WD et al. for the ORTHO EVRA/EVRA 004 Study Group: Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285 (18): 2347–54.
6. Archer DF, Bigrigg A, Smallwood GH et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 2002; 77 (Suppl. 2): S27–31.
7. Archer DF, Cullins V, Creasy GW, Fisher AC. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 2004; 69 (3): 189–95.
8. Abrams LS, Skee DM, Natarajan J, Wong FA. Pharmacokinetic overview of Ortho Evra™/Evra™. Fertil Steril 2002; 77 (Suppl. 2): S3–12.
9. Abrams LS, Skee DM, Natarajan J et al. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br J Clin Pharmacol 2002; 53 (2): 141–6.
10. Abrams LS, Skee DM, Natarajan J et al. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. J Clin Pharmacol 2001; 41 (12): 1301–9.
11. Audet MC, Moreau M, Koltun WD et al. ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285 (18): 2347–54.
12. Piccoli A, Crosignani PG, Nappi C et al. Effect of the contraceptive patch with ethinylestradiol and norelgestrominom on body composition. Results of bioelectrical impedance analysis performed in a population of women from Italy. Nutr J 2008; 7: 21 doi:10.1186/1475-2891-7-21.
13. Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol 2007; 197 (2): 134.e1–134.e6.
14. Boston Collaborative Drug Surveillance Program. Postmarketing Study of ORTHO EVRA® and Levonorgestrel Oral Contraceptives in Relation to Non-Fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction 2002–2006.
15. Creasy GW, Abrams LS, Fisher AC. Transdermal contraception. Semin Reprod Med 2001; 19 (4): 373–80.
16. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109 (2 Pt 1): 339–46. Erratum in: Obstet Gynecol 2008; 111 (6): 1449.
17. Dittrich R, Parker L, Rosen JB et al. Ortho Evra/Evra 001 Study Group. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. Am J Obstet Gynecol 2002; 186 (1): 15–20.
18. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress. Prescrire Int 2004; 13 (72): 123–6.
19. Frost JJ, Darroch JE, Remez L. Improving contraceptive use in the United States. In Brief. New York: Guttmacher Institute 2008.
20. Goebelsmann U, Mashchak CA, Mishell DR Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 1985; 151 (7): 868–77.
21. Graziottin A. A review of transdermal hormonal contraception. Focus on the ethinylestradiol/norelgestromin contraceptive patch. Treat Endocrinol 2006; 5 (6): 359–65.
22. Gallo MF, Grimes DA, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2003; 1: CD003552.
23. Harel Z, Riggs S, Vaz R et al. Adolescents' experience with the combined estrogen and progestin transdemal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol 2005; 18: 85–90.
24. Jakimiuk A, Madalenet P, Chernev T et al. Transdermal contraception is associated with high levels of patient satisfaction and compliance [abstract]. Eur J Contracept Reprod Health Care 2006; 11 (Suppl. 1): P028 68–9.
25. Jakimiuk A, Madalenet P, Chernev T et al. Efficacy and tolerability of transdermal hormonal contraception over 6 months[abstract]. Eur J Contracept Reprod Health Care 2006; 11 (Suppl. 1): P024 66–7.
26. Johnson JV, Lowell J, Badger G, Cushman M. The effects of oral and transdermal hormonal contraception on coagulation factors: a prospective, randomized, cross-over trial. Presented at: Society for Gynecologic Investigation. Toronto, ON, Canada 2006.
27. Jick S, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006; 73 (3): 223–8.
28. Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2007; 76 (1): 4–7.
29. Kubba A, Guillebaud J, Anderson RA, MacGregor EA. Contraception. The Lancet 2000; 356: 1913–9.
30. Kost K, Singh S, Vaughan B et al. Estimates of contraceptive failure from the 2002 national survey of family growth. Contraception 2008; 77 (1): 10–21.
31. LaGuardia KD, Fisher AC, Bainbridge JD et al. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril 2005; 83 (6): 1875–7.
32. Logsdon S, Richards J, Omar HA. Long-term evaluation of the use of the transdermal contraceptive patch in adolescents. Scient W J 2004; 14: 512–6.
33. Murthy AS, Creinin MD, Harwood B, Schreiber CA. Same-day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditional initiation methods. Contraception 2004; 72 (5): 333–6.
34. Petitti DB: Combination estrogen-progestin oral contraceptives. NEJM 2003; 349: 1443–50.
35. Potter L, Oakley D, de Leon-Wong E, Cañamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996; 28 (4): 154–8.
36. Jakimiuk AJ, Crosignani PG, Chernev T et al. Hhigh levels of womens satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study. Gynecol Endocrinol 2010; Early Online: 1–8.
37. Current status and future potential of transdermal drug delivery. Nature Rev Drug Discov 2004; 3 (2): 115–24.
38. Prilepskaya VN, Kabacibo C, Lee E et al. Book of abstract. 12th World congress on Human Reproduction, Venice, 2005.
39. Pierson RA, Archer DF, Moreau M et al for the ORTHO EVRA/EVRA 008 Study Group: Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003; 80 (1): 34–42.
40. Paris F, Rabeolina F, Balaguer P et al. Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line. Gynecol Endocrinol 2007; 23 (4): 193–7.
41. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998; 30: 89–92.
42. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283–8.
43. Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5-alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14 (4): 223–30.
44. Rubinstein ML, Halpern-Felsher BL, Irwin CE Jr. An evaluation of the use of the transdermal contraceptive patch in adolescents. J Adolesc Health 2004; 34 (5): 395–401.
45. Suwanmalee O, Taneepanichskul S. A clinical study of transdermal contraceptive patch in Thai women. J Med Assoc Thai 2006; 89 (Suppl. 4): S1–4.
46. Smallwood GH, Meador ML, Lenihan JP Jr et al. for the ORTHO EVRA/EVRA 002 Study Group: Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001; 98 (5 Pt 1): 799–805.
47. Schindler AE, Campagnoli C, Druckmann R et al. Classification and pharmacology of progestins. Maturitas 2003; 46 (Suppl. 1): S7–16.
48. Stewart FH, Kaunitz AM, Laguardia KD et al. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol 2005; 105 (6): 1389–96.
49. Sibai BM, Odlind V, Meador ML et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002; 77 (Suppl. 2): S19–S26.
50. Thurman AR, Hammond N, Brown HE, Roddy ME. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch? J Pediatr Adolesc Gynecol 2007; 20 (2): 61–5.
51. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol 2005; 192 (6): 2055–9.
52. World Health Organization. Medical Eligibility Criteria for Contraceptive Use: 2008 update. World Health Organization, Geneva, Swtizerland 2008.
53. Zieman M, Guillebaud J, Weisberg E et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77 (Suppl. 2): S13–8.
54. Zacur HA, Hedon B, Mansour D et al. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 2004; 77 (Suppl. 2): S32–S35.
55. Zacur HA, Hedon B, Mansour D et al. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 2002; 77 (Suppl. 2): S32–S35.

В.Н.Прилепская, Н.М.Назарова, Е.В.Иванова, А.Б.Летуновская

ФГУ Научный центр акушерства, гинекологии и перинатологии им. В.И.Кулакова Минздравсоцразвития РФ

________________________________________________

V.N.Prilepskaya, N.M.Nazarova, E.V.Ivanova, A.B.Letunovskaya 

Federal State Institution V.I. Kulakov State Research Centre for obstetrics, gynecology and perinatologyof the Ministry of Health and Social development of the Russian Federation